NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the three key mechanisms by which atebimetinib aims to improve overall survival: shrinking tumors durably. The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22, 2026 in San Diego, CA. Inhibitors of RA ...

Core Viewpoint - Analyst sentiment has turned positive for X4 Pharmaceuticals, Immuneering, and Tango Therapeutics, with new or maintained Buy ratings ahead of pivotal clinical trial readouts in 2026 [1] Group 1: Company Summaries - **X4 Pharmaceuticals (XFOR)**: Received a Buy rating from Guggenheim with a price target of $12, indicating significant upside from the current trading price of $3.97. The company raised $240.3 million, extending its cash runway to the end of 2028, and is focused on mavorixafor, a potential first-in-class oral CXCR4 antagonist [1] - **Immuneering (IMRX)**: Maintained an Overweight rating from Piper Sandler with a revised price target of $12, down from $13. The company is on track for key clinical catalysts, including updated ctDNA data and Phase 2a survival data in pancreatic cancer expected in 2026 [1] - **Tango Therapeutics (TNGX)**: Stifel raised its price target to $24 from $15 while maintaining a Buy rating. The company has seen a significant stock increase of 87.25% year-to-date and is preparing for a pivotal study in pancreatic cancer [1] Group 2: Market Performance and Analyst Ratings - All three companies have received Buy or Overweight ratings from analysts, with substantial gaps between current trading prices and analyst targets, reflecting the binary nature of clinical-stage biotech [1] - X4 Pharmaceuticals has a consensus target of $9.33, more than double its current share price, while Immuneering has gained 257.24% over the past year but is down 17.48% year-to-date [1] - Tango Therapeutics is trading close to its 52-week high, indicating that much of the near-term re-rating has already occurred, with 10 of 11 analysts rating it a Buy or Strong Buy [1]

Financial Performance - Ended 2025 with $217 million in cash, cash equivalents, and marketable securities, compared to $36.1 million at the end of 2024[4] - Net loss attributable to common stockholders for Q4 2025 was $11.6 million, or $0.18 per share, compared to a net loss of $18.1 million, or $0.58 per share, in Q4 2024[8] - Total assets increased significantly to $231,985,010 in 2025 from $52,714,413 in 2024, representing a growth of approximately 339%[18] - Current assets rose to $176,245,954 in 2025, up from $39,587,569 in 2024, marking an increase of about 344%[18] - Cash and cash equivalents surged to $128,645,025 in 2025, compared to $36,144,720 in 2024, reflecting an increase of approximately 256%[18] - Total liabilities increased to $13,501,042 in 2025 from $11,328,187 in 2024, which is an increase of about 19%[18] - Stockholders' equity grew to $218,483,968 in 2025, up from $41,386,226 in 2024, indicating a substantial increase of approximately 427%[18] - Additional paid-in capital rose to $498,658,072 in 2025, compared to $265,650,362 in 2024, representing an increase of about 88%[18] - The accumulated deficit widened to $(280,320,084) in 2025 from $(224,295,186) in 2024, reflecting a decrease in retained earnings[18] - The number of Class A common stock shares issued increased to 64,648,230 in 2025 from 31,050,448 in 2024, showing a growth of approximately 108%[18] - Total current liabilities increased to $10,073,721 in 2025 from $7,503,768 in 2024, which is an increase of about 34%[18] - The company reported no preferred stock issued or outstanding for both 2025 and 2024, maintaining a consistent capital structure in this regard[18] Research and Development - Research and Development (R&D) expenses for Q4 2025 were $9.3 million, down from $14.9 million in Q4 2024; full year R&D expenses were $42.0 million, compared to $48.0 million in 2024[8] - The company expects to dose the first patient in the pivotal Phase 3 MAPKeeper 301 trial in mid-2026[2] - Anticipated milestones include updated survival data from over 50 first-line pancreatic cancer patients in 1H 2026[4] - The company achieved alignment with FDA and EMA on the Phase 3 trial design for atebimetinib[5] Clinical Outcomes - Reported 64% overall survival at 12 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP, significantly above the 35% benchmark for standard of care[1] Market Position - Immuneering was added to the Nasdaq Biotechnology Index on December 22, 2025[5] - The cash runway is expected to fund operations into 2029[6]

Core Insights - Immuneering Corporation reported a 64% overall survival rate at 12 months for first-line pancreatic cancer patients treated with atebimetinib + mGnP, significantly higher than the standard of care benchmark of 35% [1][2][3] - The company is on track to initiate the pivotal Phase 3 MAPKeeper 301 trial in mid-2026, following alignment with the FDA and EMA on trial design [1][3] - Immuneering ended 2025 with $217 million in cash and equivalents, providing a financial runway into 2029 [1][5] Clinical Developments - The ongoing Phase 2a trial of atebimetinib + mGnP showed a median follow-up of 13.4 months with a favorable safety profile, where only neutropenia and anemia were observed at grade 3 or higher in over 10% of patients [3] - The company plans to begin dosing in a Phase 2 trial of atebimetinib + Libtayo for first-line RAS-mutant non-small cell lung cancer in the second half of 2026 [1][3] Financial Performance - For Q4 2025, research and development expenses were $9.3 million, down from $14.9 million in Q4 2024, while full-year R&D expenses decreased to $42 million from $48 million [8] - General and administrative expenses for Q4 2025 increased to $4.5 million from $3.7 million in Q4 2024, with full-year G&A expenses rising to $17.3 million from $16.1 million [8] - The net loss for Q4 2025 was $11.6 million, or $0.18 per share, compared to a net loss of $18.1 million, or $0.58 per share, in Q4 2024 [8] Strategic Positioning - Immuneering's lead product candidate, atebimetinib, is a Deep Cyclic Inhibitor targeting MEK, designed to improve survival across various cancer types, particularly those driven by the MAPK pathway [6][9] - The company has a solid pipeline and is well-positioned to advance its mission of improving patient outcomes in oncology [2][9]

Core Viewpoint - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments aimed at improving patient survival and quality of life [2] Company Overview - Immuneering is developing a new category of cancer medicines called Deep Cyclic Inhibitors, which aim to enhance overall survival through three mechanisms: durable tumor shrinkage with reduced resistance, counteracting cachexia to preserve body mass, and minimizing side effects to improve performance status and combinability [2] - The lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, targeting various cancer indications, particularly MAPK pathway-driven tumors like pancreatic cancer [2] - The company plans to initiate dosing for the MAPKeeper 301 trial in mid-2026, a pivotal Phase 3 study evaluating atebimetinib in combination with chemotherapy for first-line pancreatic cancer patients [2] Upcoming Events - Immuneering's management will present at the Leerink Global Healthcare Conference in Miami, Florida, from March 9-11, 2026, with CEO Ben Zeskind discussing the company's pipeline, platform, and business strategy [1]

Summary of Immuneering's Conference Call Company Overview - **Company**: Immuneering - **Focus**: Development of atebimetinib, a novel oral drug candidate aimed at improving survival in first-line pancreatic cancer and other cancers Key Points Industry and Product - **Industry**: Biopharmaceuticals, specifically oncology - **Product**: Atebimetinib, categorized as a Deep Cyclic Inhibitor, designed to improve overall survival through three mechanisms: tumor shrinkage, body mass preservation, and side effect minimization [2][28] Clinical Data and Comparisons - **Survival Rates**: Reported 64% overall survival at 12 months in Phase 2a study, compared to a 35% benchmark for standard care (gemcitabine/nab-paclitaxel) [2][3][10] - **Disease Control Rate**: 81% in patients treated with atebimetinib plus modified gemcitabine/nab-paclitaxel, significantly higher than the 48% benchmark for standard care [6][17] - **Progression-Free Survival**: 8.5 months, compared to 5.5 months for standard care [16] - **Overall Response Rate**: 39%, higher than the 23% benchmark from standard care [16] Mechanisms of Action - **Three Mechanisms**: 1. **Tumor Shrinkage**: Effective in both RAS and RAF-driven tumors 2. **Body Mass Preservation**: 84% of patients maintained or gained weight, counteracting cachexia [6][8] 3. **Minimizing Side Effects**: Only two categories of Grade 3 or higher adverse events (neutropenia and anemia) seen in over 10% of patients [18][19] Future Studies and Trials - **Phase 3 Study**: MAPKeeper 301, a global randomized pivotal trial, will compare atebimetinib plus modified gemcitabine/nab-paclitaxel against standard care, with overall survival as the primary endpoint [3][27] - **Patient Enrollment**: Expanded cohort of over 50 patients expected to report data in the first half of 2026 [21][22] Regulatory and Market Position - **Regulatory Alignment**: Fully aligned with FDA and EMA for the Phase 3 study [3][29] - **Market Potential**: Targeting a broad range of RAS, RAF, and other MAPK-driven cancers, which account for about half of all tumors [4][30] Key Opinion Leader (KOL) Feedback - KOLs express excitement about the triple mechanism of action, emphasizing its potential to enhance patient quality of life and survival [33][36] Conclusion - Immuneering aims to establish atebimetinib as the new standard of care in first-line pancreatic cancer, leveraging its unique mechanisms to improve patient outcomes and quality of life [46][47]

Core Viewpoint - Immuneering Corporation is a late-stage clinical oncology company focused on developing innovative cancer treatments, particularly through its lead product candidate, atebimetinib, which targets various cancer indications [1][3]. Group 1: Company Overview - Immuneering Corporation is dedicated to keeping cancer patients alive and helping them thrive by developing a new category of cancer medicines known as Deep Cyclic Inhibitors [3]. - The lead product candidate, atebimetinib, is an oral, once-daily medication designed to improve durability and tolerability for patients with MAPK pathway-driven tumors, including pancreatic cancer [3]. - A Phase 3 trial for atebimetinib in first-line pancreatic cancer is expected to begin dosing in mid-2026 [3]. Group 2: Upcoming Events - Management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, discussing the company's pipeline, platform, and business strategy [1]. - The presentation is scheduled for February 26, 2026, at 10:00 am ET and will be available via live webcast and archived on the company's Investor Relations website [2].

Core Insights - The market has experienced significant price movements among various companies, indicating a mix of company-specific developments and broader market trends [1] Company-Specific Developments - John Hancock ESG Large Cap Core Fund Class A (JHJAX) saw a dramatic price drop to $12.56, reflecting a -42.01% change, potentially due to shifts in investor sentiment towards ESG investments [2][8] - Immuneering Corporation (IMRX) experienced a stock price decline to $4.92, a -40.94% change, likely influenced by market reactions to updates from its Phase 2a trial of atebimetinib for pancreatic cancer [3][8] - MSP Recovery, Inc. (MSPR) had its price decrease to $0.05, translating to a -38.29% change, with a notable increase in short interest indicating growing bearish sentiment among investors [4][8] - CorMedix Inc. (CRMD) saw a decrease to $7.43, a -33.47% change, possibly due to challenges related to its lead product candidate and recent leadership changes [5] - Locafy Limited (LCFYW) experienced a price drop to $3, a -31.03% change, which may be linked to updates on its technology platform and market positioning [6] Market Trends and Investor Sentiment - The significant trading volumes for these companies suggest active investor engagement, likely in response to recent announcements or broader market conditions [3][4][5][6] - Understanding the underlying causes of these price changes is crucial for investors, as they reflect the dynamic nature of the stock market influenced by clinical trial results, financial performance, and strategic shifts [7]

Core Viewpoint - The article highlights the offerings of the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and live chat features for investors [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, is a private investor with a background in Applied Science, focusing on generating long-term value in the healthcare sector [2]. - The service aims to assist healthcare investors in making informed decisions through comprehensive analysis and news reports [2].

Market Performance - U.S. stocks showed mixed performance, with the Dow Jones index increasing by 0.54% to 49,261.60, while the NASDAQ fell by 0.62% to 23,437.73 and the S&P 500 dropped by 0.05% to 6,917.76 [1] - Industrial shares rose by 1.4% on Thursday, indicating strength in that sector [1] Sector Performance - Information technology stocks decreased by 1.4% on Thursday [2] Commodities - Oil prices increased by 1.8% to $56.98, while gold prices slightly decreased by 0.1% to $4,456.70. Silver fell by 3.6% to $74.820, and copper dropped by 1.7% to $5.7600 [6] European Market - European shares were mixed, with the eurozone's STOXX 600 declining by 0.27%, while Spain's IBEX 35 Index rose by 0.27%. London's FTSE 100 fell by 0.06%, Germany's DAX decreased by 0.08%, and France's CAC 40 increased by 0.06% [7] Asian Market - Asian markets closed lower, with Japan's Nikkei 225 down by 1.63%, Hong Kong's Hang Seng Index declining by 1.17%, China's Shanghai Composite slipping by 0.07%, and India's BSE Sensex falling by 0.92% [10] Company News - Flyexclusive Inc shares surged by 126% to $7.10 after being named an authorized Starlink Aviation dealer [9] - Enliven Therapeutics Inc shares increased by 54% to $23.81 following positive initial data from a clinical trial for chronic myeloid leukemia [9] - MoonLake Immunotherapeutics shares rose by 29% to $14.54 after receiving FDA feedback on its treatment for hidradenitis suppurativa [9] - Immuneering Corp shares dropped by 39% to $5.10 after announcing updated trial data for pancreatic cancer [9] - Acrivon Therapeutics Inc shares fell by 31% to $2.05 after releasing clinical data for endometrial cancer [9] - CorMedix Inc shares decreased by 23% to $8.00 following preliminary revenue results for Q4 and FY25 [9] Economic Indicators - U.S. initial jobless claims rose by 8,000 to 208,000, slightly below market expectations of 210,000 [3][12] - Nonfarm business sector labor productivity increased by 4.9% in Q3, following a revised 4.1% gain in the previous quarter [12] - Unit labor costs in the nonfarm business sector fell by 1.9% in Q3, contrasting with market expectations of a 1.0% increase [12] - The U.S. trade deficit narrowed to $29.4 billion in October, the smallest since June 2009, compared to a revised $48.1 billion in September [12]